BIOTRONIK - BIOFLOW-III Registry French Satellite

Study Overview
=================
Brief Summary
-----------------
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complications range from rather immediate elastic coil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to 50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical restenosis rates in De Novo lesions compared to PTCA alone and decreased the need for CABG. BMS substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20 to 40% of cases, necessitating repeat procedures. The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by adding an antiproliferative drug (directly immobilized on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the incidence of restenosis and resulted in better safety profile as compared to BMS with systemic drug administration. These advantages and a lower cost compared to surgical interventions has made DES an attractive option to treat coronary artery disease. Therefore this observational registry has been designed for the clinical evaluation of the ORSIRO LESS requiring coronary revascularization with DES. It is designed to investigate and collect clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting Stent System in an all-comers patient population in daily clinical practice.

Official Title
-----------------
BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite

Conditions
-----------------
Coronary Artery Diseases

Intervention / Treatment
-----------------
* Device: Drug Eluting Stent (DES)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic coronary artery disease Subject has signed informed consent for data release Subject is geographically stable and willing to participate at all follow up assessments Subject is ≥ 18 years of age Exclusion Criteria: Subject did not sign informed consent for data release Pregnancy Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Orsiro<br>Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with Diabetes (all types) at least 300 subjects should be included and analyzed in this segment Small vessels (≤2.75 mm) approx. 150 subjects Chronic total occlusion (CTO) approx. 50 subjects Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects Multivessels approx. 250 subjects In stent restenosis approx. 100 subjects Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months | Device: Drug Eluting Stent (DES)<br>* Percutaneous Coronary Intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target Lesion Failure (TLF) | Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TLF | Defined as the composite of Cardiac death, Target vessel Q-wave or non-Q wave Myocardial Infarction (MI) (i.e., Q-wave MI that cannot be attributed to a non-target vessel), clinically driven Target Lesion Revascularization (TLR) and Emergent Coronary Artery Bypass Grafting (CABG). | 6, 24, 36, 48 and 60 months | 
| Target Vessel Revascularization (TVR) | Any repeat revascularization of the target vessel. (Vascular bypass or angioplasty) | 6, 12, 24, 36, 48 and 60 months | 
| Target Lesion Revascularization (TLR) | Target Lesion Revascularization (Vascular bypass or angioplasty) | 6, 12, 24, 36, 48 and 60 months | 
| Stent Thrombosis | Definite, Probable and Possible Stent Thrombosis | 6, 12, 24, 36, 48 and 60 months | 
| Clinical Device Success | Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without use of a device outside the assigned treatment strategy. | up to 1 day | 
| Clinical Procedural Success | Successful delivery and deployment of the investigational stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple overlapping stents, if applicable) and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% of the target lesion as observed by visual estimate without using any adjunctive device* without the occurrence of ischemia-driven major adverse cardiac event (ID-MACE) during the hospital stay to a maximum of the first seven days post index procedure. | up to seven days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
national, multicenter, observational registry, Orsiro Drug Eluting Stent, Stenting Treatment of coronary artery disease, coronary revascularization, PCI, STEMI, NSTEMI, Ischemia, Angina, Acute Myocardial Infarction, Small Vessels, Chronic Total Occlusion